HIF-1α and VEGF are considered as potential targets for cancer therapy because they play an important role in the progression of many types of cancer, including leukemia, and are associated with resistance to therapy and poor prognosis [10]–[13], [43]–[45]. Here, HIF1A is linked to leukemia.